Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Caloric Restriction Slows Age-Related Loss of Neurons by Activating SIRT1

By BiotechDaily International staff writers
Posted on 06 Jun 2013
Image: Senior author Dr. Li-Huei Tsai (Photo courtesy of the Massachusetts Institute of Technology).
Image: Senior author Dr. Li-Huei Tsai (Photo courtesy of the Massachusetts Institute of Technology).
Image: To delay the onset of neurodegeneration, mice have the option to undergo a regimen of caloric restriction (represented by the scale) or a pharmacological treatment with a SIRT1-activation compound (tube labeled SRT), both of which result in reduced memory loss and preserved synaptic plasticity (Photo courtesy of Dr. Li-Huei Tsai, Massachusetts Institute of Technology).
Image: To delay the onset of neurodegeneration, mice have the option to undergo a regimen of caloric restriction (represented by the scale) or a pharmacological treatment with a SIRT1-activation compound (tube labeled SRT), both of which result in reduced memory loss and preserved synaptic plasticity (Photo courtesy of Dr. Li-Huei Tsai, Massachusetts Institute of Technology).
Caloric restriction (CR), a dietary regimen known to promote lifespan by retarding the onset of age-dependent diseases, has been found to slow the progressive loss of neurons associated with impaired cognitive capacity by activating the enzyme sirtuin 1 (SIRT1, silent mating type information regulation 2 homolog 1).

Investigators at the Massachusetts Institute of Technology (Cambridge, USA) speculated that since aging is the greatest risk factor for neurodegeneration in the brain, CR might slow the progressive loss of neurons. To explore this possibility they used a genetically engineered mouse model that allowed for temporally and spatially controlled onset of neurodegeneration. These animals were fed a diet decreased by 30% from the normal mouse diet for three months.

Results published in the May 22, 2013, issue of the Journal of Neuroscience revealed that CR significantly delayed the onset of neurodegeneration and synaptic loss and dysfunction, and thereby preserved cognitive capacities.

“We not only observed a delay in the onset of neurodegeneration in the calorie-restricted mice, but the animals were spared the learning and memory deficits of mice that did not consume reduced-calorie diets,” said senior author Dr. Li-Huei Tsai, professor of brain and cognitive sciences at the Massachusetts Institute of Technology. “The question now is whether this type of treatment will work in other animal models, whether it is safe for use over time, and whether it only temporarily slows down the progression of neurodegeneration or stops it altogether



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.